Compare REFI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REFI | CCCC |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.8M | 404.7M |
| IPO Year | 2021 | 2020 |
| Metric | REFI | CCCC |
|---|---|---|
| Price | $10.77 | $3.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 143.7K | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 15.79% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $48,857,628.00 | $35,947,000.00 |
| Revenue This Year | $17.47 | N/A |
| Revenue Next Year | $0.06 | N/A |
| P/E Ratio | $18.88 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $9.69 | $1.69 |
| 52 Week High | $13.72 | $5.17 |
| Indicator | REFI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 35.36 |
| Support Level | $10.63 | $3.40 |
| Resistance Level | $10.93 | $3.91 |
| Average True Range (ATR) | 0.18 | 0.20 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 25.84 | 9.09 |
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.